Pulmonx Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Pulmonx şirketinin toplam hissedar öz sermayesi $93.9M ve toplam borcu $37.2M olup, bu da borç-öz sermaye oranını 39.6% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $167.4M ve $73.5M dir.

Anahtar bilgiler

39.6%

Borç/özkaynak oranı

US$37.24m

Borç

Faiz karşılama oranı	n/a
Nakit	US$107.78m
Eşitlik	US$93.93m
Toplam yükümlülükler	US$73.48m
Toplam varlıklar	US$167.40m

Son finansal sağlık güncellemeleri

Is Pulmonx (NASDAQ:LUNG) Using Debt In A Risky Way?

Oct 02

Pulmonx (NASDAQ:LUNG) Has Debt But No Earnings; Should You Worry?

Feb 23

Recent updates

Not Many Are Piling Into Pulmonx Corporation (NASDAQ:LUNG) Stock Yet As It Plummets 27%

Oct 22

Is Pulmonx (NASDAQ:LUNG) Using Debt In A Risky Way?

Oct 02

Pulmonx Corporation (NASDAQ:LUNG) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Aug 15

Pulmonx: Low Bar For Q2 Earnings

Jul 21

Slammed 26% Pulmonx Corporation (NASDAQ:LUNG) Screens Well Here But There Might Be A Catch

Jun 07

Analysts Just Shaved Their Pulmonx Corporation (NASDAQ:LUNG) Forecasts Dramatically

Nov 08

Pulmonx GAAP EPS of -$0.40 in-line, revenue of $14M beats by $0.23M

Aug 02

Pulmonx: Interesting Technology But Struggling With Adoption

Jul 02

These Analysts Just Made A Meaningful Downgrade To Their Pulmonx Corporation (NASDAQ:LUNG) EPS Forecasts

Feb 28

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: LUNG 'nin kısa vadeli varlıkları ( $140.9M ) kısa vadeli yükümlülüklerini ( $18.3M ) aşıyor.

Uzun Vadeli Yükümlülükler: LUNG şirketinin kısa vadeli varlıkları ( $140.9M ) uzun vadeli yükümlülüklerini ( $55.2M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: LUNG şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: LUNG 'nin borç/öz sermaye oranı son 5 yılda 371% seviyesinden 39.6% seviyesine düştü.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: LUNG şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: LUNG, serbest nakit akışı her yıl % 9.9 oranında tarihi oranda azalmaya devam ederse 3 yıldan fazla bir süre yeterli nakit akışına sahip olur

Pulmonx Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Pulmonx (NASDAQ:LUNG) Using Debt In A Risky Way?

Pulmonx (NASDAQ:LUNG) Has Debt But No Earnings; Should You Worry?

Recent updates

New minor risk - Share price stability

Third quarter 2024 earnings: EPS exceeds analyst expectations

Not Many Are Piling Into Pulmonx Corporation (NASDAQ:LUNG) Stock Yet As It Plummets 27%

Director notifies of intention to sell stock

Pulmonx Corporation to Report Q3, 2024 Results on Oct 30, 2024

Is Pulmonx (NASDAQ:LUNG) Using Debt In A Risky Way?

Director notifies of intention to sell stock

New minor risk - Share price stability

CEO, President & Director recently bought US$97k worth of stock

Pulmonx Corporation (NASDAQ:LUNG) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Pulmonx Corporation Maintains Revenue Guidance for the Full Year of 2024

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Pulmonx: Low Bar For Q2 Earnings

Pulmonx Corporation to Report Q2, 2024 Results on Jul 31, 2024

Slammed 26% Pulmonx Corporation (NASDAQ:LUNG) Screens Well Here But There Might Be A Catch

Price target decreased by 8.4% to US$14.83

Pulmonx Corporation Provides Revenue Guidance for the Full Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Pulmonx Corporation to Report Q1, 2024 Results on May 01, 2024

Pulmonx Corporation, Annual General Meeting, May 16, 2024

Pulmonx Corporation's (NASDAQ:LUNG) Share Price Matching Investor Opinion

Pulmonx Corporation Announces Chief Financial Officer Changes, Effective April 3, 2024

Pulmonx: Revisiting Thesis Following Management Change

Consensus EPS estimates fall by 13%, revenue upgraded

Pulmonx Corporation Announces Treatment of the First Patient with the Aeriseal System in Convert II Pivotal Trial

Pulmonx (NASDAQ:LUNG) Has Debt But No Earnings; Should You Worry?

Pulmonx Corporation Announces Chief Executive Officer, Effective March 15, 2024

CEO, President & Director notifies of intention to sell stock

Pulmonx Corporation to Report Q4, 2023 Results on Feb 21, 2024

CEO, President & Director notifies of intention to sell stock

CEO, President & Director notifies of intention to sell stock

CEO, President & Director recently sold US$69k worth of stock

Price target decreased by 12% to US$14.83

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Pulmonx Corporation Provides Earnings Guidance for 2023

Pulmonx Corporation to Report Q3, 2023 Results on Oct 30, 2023

Pulmonx Corporation Announces Chief Financial Officer Changes

CEO, President & Director recently sold US$65k worth of stock

Price target increased by 7.4% to US$15.57

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Pulmonx Corporation Updates Revenue Guidance for Fiscal Year 2023

Market Participants Recognise Pulmonx Corporation's (NASDAQ:LUNG) Revenues

CEO, President & Director notifies of intention to sell stock

Pulmonx Corporation to Report Q2, 2023 Results on Aug 02, 2023

Price target increased by 9.1% to US$14.50

CEO, President & Director notifies of intention to sell stock

CEO, President & Director recently sold US$75k worth of stock

Pulmonx Corporation Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 12% to US$12.43

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Pulmonx Corporation to Report Q4, 2022 Results on Feb 22, 2023

Pulmonx Receives Japanese MHLW Approval of Zephyr Endobronchial Valve for the Treatment of Severe COPD/Emphysema

Price target decreased to US$13.07

High number of new directors

Analysts Just Shaved Their Pulmonx Corporation (NASDAQ:LUNG) Forecasts Dramatically

Third quarter 2022 earnings released: US$0.38 loss per share (vs US$0.28 loss in 3Q 2021)

Pulmonx Corporation Revises Earnings Guidance for the Full Year of 2022

Pulmonx Corporation to Report Q3, 2022 Results on Nov 03, 2022

CEO, President & Director notifies of intention to sell stock

Pulmonx Corporation Announces the Presentation of Interim Results from the Convert Study At the 2022 European Respiratory Society (Ers) International Conference

CEO, President & Director recently sold US$53k worth of stock

CEO, President & Director notifies of intention to sell stock

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Pulmonx Corporation Provides Revenue Guidance for the Full Year 2022

Pulmonx GAAP EPS of -$0.40 in-line, revenue of $14M beats by $0.23M

Pulmonx Corporation to Report Q2, 2022 Results on Aug 02, 2022

Price target decreased to US$28.00

Pulmonx: Interesting Technology But Struggling With Adoption

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Pulmonx Corporation Provides Revenue Guidance for the Full Year 2022